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Abstract: Inflammation is a hallmark in many forms of cancer; with colitis-associated colorectal
cancer (CAC) being a progressive intestinal inflammation due to inflammatory bowel disease (IBD).
While this is an exemplification of the negatives of inflammation, it is just as crucial to have some
degree of the inflammatory process to maintain a healthy immune system. A pivotal component in
the maintenance of such intestinal homeostasis is the innate immunity component, inflammasomes.
Inflammasomes are large, cytosolic protein complexes formed following stimulation of microbial and
stress signals that lead to the expression of pro-inflammatory cytokines. The NOD-, LRR- and pyrin
domain-containing protein 3 (NLRP3) inflammasome has been extensively studied in part due to
its strong association with colitis and CAC. The aryl hydrocarbon receptor (AhR) has recently been
acknowledged for its connection to the immune system aside from its role as an environmental sensor.
AhR has been described to play a role in the inhibition of the NLRP3 inflammasome activation
pathway. This review will summarise the signalling pathways of both the NLRP3 inflammasome
and AhR; as well as new-found links between these two signalling pathways in intestinal immunity
and some potential therapeutic agents that have been found to take advantage of this link in the
treatment of colitis and CAC.
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut that includes
ulcerative colitis (UC) and Crohn’s disease (CD) [1]. While the incidence of IBD only occurs in
1–2% of all colorectal cancer (CRC) patients in the general population [2], this incidence has been
quantified to increase up to 5% in patients suffering over 20 years of the disease [3]. The risk of
CRC development rises in patients with IBD and is a more belligerent carcinoma with an earlier age
of onset than sporadic CRC [2]; with the major driving force of carcinogenesis being inflammation
and immunosuppression [4]. This has led to a poor prognosis for patients with IBD, with 1 in 6
patients dying from cancer [5]. Molecular changes and mutations in colitis-associated colorectal cancer
(CAC) are linked to inflammation-driven by dysregulated cytokines and inflammatory mediators
corresponding to IBD, which alter cell communication, cell-to-cell signalling and cell adhesion [6]. In
the Australian context, colorectal cancer is projected to become the most expensive cancer to treat; with
financial costs of treatment estimated to increase from AUS$1 billion in 2013 [7] to AUS$2 billion in
2040, excluding screening programs [8]. Recently, inflammasomes have been recognised as the main
driving force in the mucosal inflammatory process.
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Inflammasomes are large cytosolic protein complexes that have been recognised as a major
component of the innate immunity [9]. These high molecular weight complexes function to
mediate the host defence mechanism against microbial infections and danger-associated endogenous
stimuli [9,10] The initiation of inflammatory signalling cascades that lead to the proteolytic cleavage of
pro-caspase-1 into caspase-1 that activates the cytokine precursors, pro-IL-1β and pro-IL-18, leading to
pyroptosis [11,12]. Pattern-recognition receptors (PRRs), which consist of toll-like receptors (TLRs)
and nod-like receptors (NLRs), serve as the initiators of this signalling cascade when they recognise
pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs),
resulting from pathogens, endogenous stress and particulate matters [13].
In this review, we will comprehensively describe the role that the aryl hydrocarbon receptor
(AhR) plays in the inhibition of NLRP3 inflammasome and its effects on CRC. While some studies
have described the strong association between AhR and NLRP3, they have not explored the cross-over
between the signalling pathways of AhR and NLRP3 extensively. The signalling pathways of AhR will
be described and the link between these pathways with the NLRP3 signalling pathways will be explored.
The therapeutic potential of AhR will also be discussed, with examples of novel therapeutic agents
that involve the immunomodulation of AhR.
2. Biological Features of the NLRP3 Inflammasome
The NLRP3 inflammasome is one of the most extensively studied NLRs due to its clinical
relevance in a wide range of human diseases. This 115 kDa cytosolic protein complex consists of a
triadic constitution; the NACHT scaffold which serves as a central oligomerization domain with an
ATPase activity, the N-terminal PYCARD adaptor which recruits the apoptosis-associated speck-like
protein (ASC) and the C-terminal leucine-rich repeat (LRR) which are thought to be involved in
detecting stimuli [11,14].
2.1. The NLRP3 Inflammasome Canonical Pathway
The canonical pathway (Figure 1) requires a two-step process which is proposed to be mediated
at both the transcriptional and post-transcriptional levels [15], known as priming (signal 1) and
activation (signal 2). Signal 1 involves a priming signal that is generated by TLR4 agonists through
the TLR/nuclear factor (NF)-kB pathway that positively induces the expression of NLRP3, pro-IL-1β
and pro-IL-18. Signal 2 involves the detection of PAMPs and DAMPs that lead to the formation of the
NLRP3 inflammasome [15,16].
Priming is a necessary step in canonical NLRP3 activation as it ensures that NLRP3 activation
is a controlled process to prevent harmful effects on the host and that once priming commenced,
the macrophage would commit to activating the NLRP3 inflammasome [17]. Within the priming
step itself, there are also several pathways identified; which can be classified as transcriptional
and non-transcriptional pathways [18]. The transcriptional priming pathway (>3 h) involves the
activation of the NF-κB signalling pathway; with Bauernfeind et al. concluding that the disruption
to the NF-κB signalling pathway activators or its components; such as MyD88, IRAK1 and IRAK4,
lead to the reduction in NLRP3 expression in human monocytes, even when treated with signal
2 [17]. The non-transcriptional pathways both rely on post-transcriptional modifications (PTM) and
mitochondrial ROS and can be effective within 10–30 min (MyD88 binding) or 30–60 min (TRIF binding)
after TLR activation through their own respective pathways [18]. Through PTM by phosphorylation
and ubiquitination, the lengthy duration for transcriptional priming can be bypassed, providing rapid
priming of NLRP3. The PTM of NLRP3 inflammasome during priming will be discussed further below.
Following priming, NLRP3 is licenced to be activated by its diverse activation signals; but not
directly bound to the complex [11], that leads to the secretion of the proinflammatory cytokines IL-1β
and IL18; as well as stimulate pyroptosis in the cell through disrupting the osmotic potential due to
cytoplasmic Gasdermin-D (GSDMD-D) forming pores [18]. There would be an underlying molecular
mechanism to allow these activation signals; PAMPs and DAMPs, to indirectly activate the NLRP3
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inflammasome; which have been proposed to be through ion fluxes, mitochondrial dysfunction and
ROS production, cathepsin B and lysosomal rupture and PTM of NLRP3 [19].
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2.1.1. Ion Fluxes
The efflux of K+ is an established model that is an important component to the activation of NLRP3
inflammasome, which precedes mitochondrial dysfunctions [20] and proposed to occur upstream
of NLRP3 activation, further supporting that K+ efflux takes place prior to NLRP3 activation [11].
The generic NLRP3 activators, ATP and nigericin, modify intracellular components and decrease
intracellular K+ concentrations through non-selective K+ conduction out of the cell across the plasma
membrane [15] by pores formed on the plasma membrane; such as the P2X7 ATP gated ion channels [19],
which lead to a conformational change in NLRP3 inflammasome-forming oligomers [18]. While K+ is
important, it is unspecific and not required for NLRP3 inflammasome activation as there are studies
that have shown that small molecules; such as imiquimod and CL097 [21], and macrophage models
that have the NLRP3 activating mutation (NLRP3R258W) can still activate NLRP3 independent of K+
efflux [11]. There is also evidence that supports the notion that Cl− efflux can also lead to the activation
of NLRP3; through the use of NSAIDs that inhibit the membrane Cl−-channel, VRAC, which suppressed
NLRP3 activation, by interfering with NLRP3-NEK7 interactions [16,22,23]. While there is evidence
of Na+ influx and Zn2+ inducing NLRP3 activation, they are not conclusive and there is a possibility
that Na+ influx is dependent on K+ efflux [16,21]. Ca2+ signalling has also been associated with
NLRP3 inflammasome activation. There are propositions to how an increased Ca2+ is integrated
with NLRP3 activation, which describe that a rise in extracellular K+ promotes both K+ efflux and
an increased cytosolic Ca2+, inferring a link between K+ and Ca2+ ionic balance [18] or that Ca2+
overload due to excessive release from storage in the endoplasmic reticulum leads to mitochondrial
dysfunction, which results in the production of ROS [16,21]. However, further studies are required to
determine its significance and understand the mechanisms behind Ca2+ signalling in the activation of
NLRP3 inflammasome.
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2.1.2. Mitochondrial Dysfunction and ROS Production
Another proposed model of NLRP3 inflammasome activation is the production of cytosolic ROS
by NADPH oxidase following mitochondrial dysfunction in consequence of endogenous stress from
the detection of various NLRP3 agonists [11,16,19]. The influence of mitochondrial dysfunction on
NLRP3 activation was identified from several studies that manipulated mitochondrial ROS production
through induction with agonists and antagonists. This was achieved through the inhibition of NLRP3
activation via the blocking of mitochondrial ROS production [24]. Contrary to this, another study found
that the stimulation of mitochondrial ROS production promoted NLRP3 activation [25]. Wen et al.
demonstrated that inhibition of autophagy to remove non-functioning mitochondria via AMPK
pathway, lead to upregulated ROS production and NLRP3 activation and IL-1β release, in response to
LPS [26]. Following the detection of NLRP3 agonists, thioredoxin-interacting protein (TXNIP) activates
the NLRP3 inflammasome via a ROS-dependent manner through binding to the LRR domain of
NLRP3 [19]. The study further demonstrated that there was a deficiency in the activation of caspase-1
and expression of IL-1β during inhibition of TXNIP; which suggests that there are other models that
work in tandem with the ROS model to regulate NLRP3 activation [19]. Another study also implicated
the role of mitochondrial antiviral-signalling protein (MAVS) in NLRP3 activation but was unclear on
the mechanism regulating its role [27]. Therefore, further studies must be conducted to determine the
role that ROS model plays in NLRP3 activation.
2.1.3. Cathepsin B and Lysosomal Rupture
In addition to ion fluxes and ROS production, lysosomal rupture has also been proposed as a
model for NLRP3 inflammasome activation. Lysosomal rupture occurs from endocytosis of particulate
matter, microbial pathogens and sterile environmental matter; which results in the release of the
lysosomal protein cathepsin B [15]. Even though cathepsin B is the primary focus, other cathepsins
have been indicated to also promote IL-1β secretion and NLRP3 inflammasome activation [28]. This is
the case in a study by Duewell et al. which exhibited a reduction in IL-1β secretion when induced by
cholesterol crystals to activate the NLRP3 inflammasome in mouse models deficient in cathepsin B
or L as compared to wild types, and that phagolysosomal rupture was an essential event in NLRP3
activation [29]. Another study determined that the irreversible cathepsin B inhibitor, CA-074Me,
inhibited NLRP1b-mediated caspase-1 activation when triggered by anthrax lethal toxins [30]. There is
also evidence that demonstrated that Group B streptococci, malarial parasites and adenovirus type-5
require lysosomal rupture induce NLRP3 inflammasome activation [31–33]. There is also a link
established between lysosomal rupture and K+ efflux, similar to ROS production; further solidifying
the notion of K+ efflux being the common trigger for NLRP3 inflammasome activation. Another
recent study by Munoz-Planillo et al. found that LPS priming stimulated an increased K+ efflux when
activated by particulate matter; including the lysosomal-damaging dipeptide LL-OMe, due to the K+
efflux opening one or multiple K+ permeable membrane pores [20].
2.2. The NLRP3 Inflammasome Non-Canonical Pathway
The non-canonical pathway (Figure 2) is another NLRP3 activation pathway model that differs
slightly from the canonical pathway due to the utilisation of caspase-4/5 (in humans) or caspase-11
(in mice) to release the proinflammatory cytokines, IL-1β and IL-18 and triggering pyroptosis. This
pathway can be activated by most Gram-negative bacteria but not Gram-positive bacteria, which
suggests that LPS plays a major role in this pathway [11,16]. Priming is a necessary step in the
non-canonical pathway in mouse models due to reduced caspase-11 expression in resting cells; however,
this is not the case in human models due to the expression of caspase-4 in many non-monocytic cells
and monocytes [16]. Intracellular LPS is able to bind directly to the CARD domain of caspase-4/5/11 to
stimulate oligomerisation and activation of these caspases, which cleave GSDMD-D into two fragments;
N-domain and C-domain, that lead to the formation of pores on the plasma membrane and allow K+
Molecules 2020, 25, 2427 5 of 25
efflux and pyroptosis to occur [11,16]. However, the caspases will not cleave and activate pro-IL-1β
and pro-IL-18; instead, K+ efflux due to the pores formed will induce NLRP3 activation through the
canonical pathway, inferring a link between the canonical and non-canonical pathway [16].
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2.3. The NLRP3 Inflammasome Alternate Pathway
While both the canonical and non-canonical pathways follow a two-signal mechanism, there is
evidence to show that human monocytes; unlike macrophages, can be triggered by TLR ligands alone;
such as LPS. This process is done in the absence of K+ efflux; the common NLRP3 activation
model, to activate caspase-1 and release mature IL-1β through the ATP-P2X7 pathway, without
causing cell death [34,35]. This separation betw en the release of proinflammatory cytokines and
non-reversible pyroptosis diversifies the roles the host defence can play in a greater variety of
situations. This pathway (Figure 2) requires the activation of caspase-8 by cleaving through the
TLR4–TRIF–RIPK1–FADD signalling pathway; though the actual mechanisms to cleave caspase-8 is
still unclear [36]. Antonopoulos et al. suggested that caspase-8 may substitute the role of caspase-1 in
inducing pore formation during pyroptosis and IL-1β processing [37]. This is in line with the results
observed by Chung et al. who also identified that caspase-8 forms a complex with NLRP3 and ASC to
induce apoptosis [38]. This stance is supported by Gringhuis et al. who identified that the dectin-1
PRR elicited pro-IL-1β activation following the detection of a specific fungal ligand via a caspase-8
dependent mechanism [39]. Contrary to this notion, Gaidt et al. have proposed that caspase-8 does
not directly cleave IL-1β due to failure for Nlrp3-/-, Asc-/- and Caspase-1-/- monocytes to secrete IL-1β
after LPS induction; and that the NLRP3 inhibitor, MCC950 can also block activation of the alternate
pathway [40]. Additional studies are required to clarify the specific mechanisms involved but it is clear
that caspase-8 plays an integral role in the alternate pathway activation of the NLRP3 inflammasome.
2.4. Regulation of NLRP3 Inflammasome
As previously mentioned, PTM occurs in both the priming and activation step of the NLRP3
inflammasome and each component is important to maintain balance in the inflammatory response [41].
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2.4.1. Post-Translational Modifications during the Priming Step
The priming step of NLRP3 inflammasome can be shortened by utilising a non-transcriptional
mechanism through TLR4-MyD88 signalling [42,43]. This suggests that regulation of PTM during
priming is essential as part of the NLRP3 inflammasome activation pathway, in addition to
transcription. The ubiquitin system consists of the addition of ubiquitin; ubiquitination, and the
removal of ubiquitin; deubiquitination, both of which are part of the PTM of protein during NLRP3
inflammasome activation. An important study outlined the role that PAMPs and DAMPs play in
modulating deubiquitinase activity. This same study also identified USP7 and USP47 as integral
components in canonical NLRP3 inflammasome activation [44], further highlighting the importance
of deubiquitinases. The direct phosphorylation of NLRP3 at Ser194 (Ser198 in humans [18]) by
c-Jun terminal kinase 1 (JNK1), which has interactions with BRCA1–BRCA2-containing complex
subunit 3 (BRCC3, a Lys63-specific deubiquitinase), has been shown to play a central role in NLRP3
deubiquitination during NLRP3 priming [45–47]. Humpries et al. provided the first description of the
role played by E3 ubiquitin ligase Pellino2 in mediating the K63-linked ubiquitination of the NLRP3
inflammasome priming; through ubiquitination of the negative regulator IRAK1 [48]. In addition to that,
phosphorylation of IKKs also have a role in NLRP3 inflammasome priming; with IKKα phosphorylation
at S193 and S16 of ASC allowing sequestration of ASC in the nucleus, IKKi phosphorylation at S58
facilitating ASC translocation from the nucleus to the cytoplasm [49] and IKKγ/NF-κB essential
modulator (NEMO) phosphorylation at S337 suppressing NF-κB activation [50]. Aside from NF-κB
being involved in PTM, several components of MAPK were also found to have an impact in the
priming step of NLRP3 activation via PTM. The external signal regulated kinase1 (ERK1) has been
implicated in the NLRP3 inflammasome priming event; with a study by Ghonime et al. employing
Erk1 knockdown mouse models leading to impaired priming [51]. This notion was supported by
D’Espessailles et al. which found that G protein-coupled calcium-sensing receptor (CaSR)-dependent
NLRP3 inflammasome activation uses the ERK1/2 signalling pathway [52]. This was also the case for
p38 MAPK phosphorylation being an essential step in NLRP3 inflammasome priming with several
studies showing a reduction in p38 activation through inhibition studies. These studies found that
p38 MAPK signalling inhibitor SB203580 reducing NLRP3 inflammasome expression [53]. They also
determined that Levistilide A reducing NLRP3 inflammasome expression through blocking of the
Syk-p38/JNK pathway [54]. Blocking of the NLRP3-associated stress signals; K+ efflux, ROS production
and cathepsin B, was also concluded to lead to a blockade of p38δ MAPK activation [55]. A series of
studies also establish that C5a-C5aR2 complement crosstalk with protein kinase R (PKR) promotes
NLRP3 inflammasome activation via MEK/ERK signalling and type I IFN signalling [56–58]. Finally,
there was also a study by Basak et al. which illustrated that LPS derived from H. pylori can lead to the
phosphorylation of caspase-1 at Ser376 through the PI-3K/Rac1/p21-activated kinase (PAK) 1 signalling
pathway and is crucial for activation of caspase-1 [59].
2.4.2. Post-Translational Modifications During the Activation Step
In addition to PTM during the NLRP3 inflammasome priming step, a diverse range of PTM has
also been described in its activation step. Protein kinase A (PKA) has been found to negatively regulate
NLRP3 activation by phosphorylation at Ser295 (Ser291 in mouse models) in the NACHT domain;
which is the site for cryo-pyrin-associated periodic syndromes (CAPS)-associated NLRP3 mutations [60],
via TGR5-cAMP-PKA axis [61] and prostaglandin E2 receptor E-prostanoid 4 (EP4) axis [62]. In contrast
to this, Zhang et al. found that Golgi-mediated protein kinase D (PKD) phosphorylation at the
Ser295 site leads to the release of mitochondria-associated membrane (MAM) that promotes NLRP3
inflammasome activation [63]; further solidifying Ser295 phosphorylation as an important event in
the regulation of the NLRP3 inflammasome activation. The E3 ligase, Ariadne homolog 2 (ARIH2)
was also shown to negatively regulate NLRP3 inflammasome activity in macrophages via NLRP3
ubiquitination linked through K48 and K63 in the NACHT domain [64]. In addition to ARIH2, there
are other E3 ligases that have implications in NLRP3 inflammasome activation; with Tripartite Motif
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Containing 31 (TRIM31) promoting K48-linked polyubiquitination and proteosomal degradation of
NLRP3 [65] and F-box L2 (FBXL2) promoting ubiquitin ligation at Lys-689 within NLRP3 and promote
its degradation [66]. Similar to FBXL2, F-box-only protein 3 (FBXO3); another F-box protein, is involved
in the LPS-induced NLRP3 inflammasome priming and is responsible for the ubiquitination and
degradation of FBXL2 [66]. There is also evidence that shows that the neurotransmitter, dopamine,
negatively regulates NLRP3 inflammasome activation via the cAMP-mediated dopamine D1 receptor
(DRD1) signalling pathway by promoting its ubiquitination and degradation via the E3 ubiquitin ligase,
MARCH7 [67]. In addition to protein kinases, Stutz et al. have described phosphatases to be involved
in the regulation of the NLRP3 inflammasome; such as phosphatase 2A (PP2A) dephosphorylating the
pSer5 residue at the NLRP3 PYD domain to promote NLRP3 inflammasome activation [68]. In addition,
Spalinger et al. described protein tyrosine phosphatase non-receptor 22 (PTPN22) to dephosphorylate
the Tyr861 site to prevent excessive NLRP3 inflammasome activation [69].
2.5. The NLRP3 Inflammasome and IBD
There is still a disparity in the results from many studies that describe the role NLRP3 plays on
colitis as a protective or detrimental one [12]. However, recent studies have shown the success of NLRP3
inhibitors in ameliorating colitis and in turn CAC, providing strong evidence that an overactivation
of NRLP3 is detrimental to intestinal homeostasis. Some inhibitors act to directly disrupt functional
components of the NLRP3 inflammasome activation pathway. MCC950 has been found to suppress
the transcription and translation of IL-1β and IL-18 in both canonical and non-canonical pathways [70].
Curcumin was determined to prevent the key events in the activation step (Signal 2) of the NLRP3
activation pathway; which include K+ efflux, ROS formation and cathepsin B release, thus preventing
NLRP3 inflammasome activation [71]. Wogonoside was described to inhibit NF-κB activity, which
prevents NLRP3 activation in the colon [72]. On the other hand, other inhibitors have attenuated
the effects of colitis through indirect interactions with the NLRP3 inflammasome. Arctigenin acts
to inhibit NLRP3 inflammasome activation via SIRT1, which functions to suppress the expression
of inflammatory genes [73]. Palmatine was found to facilitate a specialised autophagy pathway,
the PINK1/Parkin-driven mitophagy, which inactivates NLRP3 in macrophages [74]. Formononetin
was described to promote the expression of epithelial cell tight junctions, which are prominently
reduced in DSS-induced colitis, and maintained the colonic epithelial barrier [75]. Cinnamaldehyde
was described to ameliorate ulcerative colitis through the suppression of miR-21 and miR-155 in the
colon and macrophage [76].
It is clear that IL-1β is an integral component of the pool of pro-inflammatory cytokines present
during inflammation in IBD patients [77]. The role of the NLRP3 inflammasome as a regulator of IL-1β
maturation strengthens the notion that it plays a vital role in the development of IBD. As previously
mentioned, several studies utilised NLRP3 inhibitors to ameliorate the effects of DSS-induced colitis.
A recent study investigated this premise through a different perspective; by utilising an NLRP3
activator, the Jumonji domain-containing 3 (Jmjd3). This study found that Jmdjd3 promoted NLRP3
inflammasome regulation and exacerbated DSS-induced colitis in mice [78]. Genetic studies have also
found that single nucleotide polymorphisms (SNP) of the NLRP3 gene were highly associated with an
increased susceptibility to CD [79]. These evidences strongly suggest that overactivation of the NLRP3
inflammasome leads to the overexpression of pro-inflammatory cytokines that promote inflammation
and the development of IBD.
In addition, a non-cytotoxic, acrylate-based NLRP3 inhibitor (INF39) was successfully developed
that attenuated colitis through irreversible inhibition of the NLRP3 ATPase activity [80]. A follow-up
study found that this direct NLRP3 inhibition by INF39 was more effective than caspase-1 or IL-1β
suppression in ameliorating the effects of colitis [81]. This suggests that there is therapeutic potential
for direct NLRP3 inhibition in the treatment of bowel inflammation [82].
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2.6. The NLRP3 Inflammasome and CRC
Due to the effects of chronic inflammation that may be involved with tumorigenesis and the
influence of the NLRP3 inflammasome on triggering and promoting inflammation; NLRP3 has been
linked to many human malignancies, though its exact mechanisms remain unclear [83]. While NLRP3
is necessary for anticancer adaptive immune responses, its activation has also been related to several
types of cancer due to the release of IL-1β and IL-18; including CRC, CAC, fibrosarcoma, transplantable
tumour, lung cancer, thymoma, gastric cancer, hepatocellular carcinoma, breast tumours, head and
neck cancers, prostate cancer, cervical cancer and central nervous system tumours [83,84].
A crucial study found that NLRP3 was overexpressed in CRC-positive tissue; adding that this high
expression of NLRP3 was correlated with shorter lifespans and a poorer prognosis [85]. This notion
was supported by a genetic study that showed that genetic alterations in the NF-κB axis influence
prognosis of CRC patients [86]. Another study determined that NLRP3 expression was a prerequisite
for epithelial-mesenchymal transition in colorectal cancer cells [87]; suggesting the role of NLRP3 in
promoting cell migration and proliferation during CRC.
3. Biological Features of the Aryl Hydrocarbon Receptor
The aryl hydrocarbon receptor (AhR) is a member of the basic helix–loop–helix (bHLH) family of
transcription factors. It is composed of three domains, each with its own functions. The N-terminal
bHLH domain facilitates binding of AhR to the consensus regulatory sequences (5′-T/GCGTG-3′) of
DNA [14,88]. The C-terminal variable domain promotes binding of AhR with its partner protein ARNT
to form a heterodimeric complex [14,88]. The DNA-binding PER-ARNT-SIM (PAS) domain consists of
PAS-A and PAS-B that is involved in secondary interactions with ARNT to ensure the formation of the
heterozygous complex [14,88]. While it was discovered to have an integral role in the alleviation of
toxic effects from environmental pollutants [88], recent studies have discovered its importance in the
context of immunity and many cellular pathways.
3.1. AhR Exogenous Ligands
Most of the classical, high-affinity AhR ligands are environmental contaminants which
consist of halogenated aromatic hydrocarbon (HAH), polycyclic aromatic hydrocarbons (PAH)
and polychlorinated biphenyls (PCB); with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) being one
of the most potent and well-studied HAH ligands that can activate AhR receptors at picomolar
concentrations [89]. HAHs are metabolically more stable [90] and are generally environmental
waste resulting from industrial accidents or waste incineration products; which remain stable when
extensively halogenated, but become potent AhR agonists when halogenated at lateral positions of the
coplanar rings [91]. Chlorinated members of HAH agonists are known to elicit toxic responses that
include epithelial hyperplasia, tumour promotion, teratogenesis, thymic involution and death [91].
PCBs are used in a wide variety of commercial products; including insulators, flame retardants and
adhesives, due to their chemical stability and their potency are dependent on the halogens present on
their benzene rings and the degree of substitution at their biphenyl bridge [91]. 3,3′,4,4′,5′-PentaCB is
the most potent of the PCBs, but are still 100 times less potent than TCDD [91]. PAHs are metabolically
more labile [90] and are commonly used in combustion processes; including chimney soot, charbroiled
foods and smoke exhaust, which usually contain four or more conjugated benzene rings with a potency
three to four-fold less than that of TCDD [91]. PAHs induce their own metabolisms due to their role as
a substrate for the phase I and II xenobiotic metabolising enzymes [91].
3.2. AhR Endogenous Ligands
3.2.1. Tryptophan Metabolites
Tryptophan is one of the nine essential amino acids which acts as a precursor for many physiological
functions in the body. Due to its aromaticity [91] and metabolism by spontaneous and enzyme-catalysed
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conversions and associated microbiota being a physiological source of numerous AhR agonists, it has
been described to play a central role in many endogenous AhR ligands [92,93]. The main metabolic
pathway (>90%) [92] of tryptophan in the body is the kynurenine (KYN) pathway via the enzyme
isoforms indoleamine 2,3-dioxygenase (IDO1/2) and tryptophan 2,3-dioxygenase (TDO1/2) [92,94]
driving in an inflammatory and carcinogenic pathway [93]. KYN is an intermediate-affinity AhR
ligand with functions in Treg maturation and suppression of DCs [88]. This pathway leads to a
positive feedback loop due to IDO being induced by AhR [95] and KYN metabolism can also lead to
the production of kynurenic acid, xanthirenic acid and cinnabarinic acid, which are also potent AhR
ligands [93].
In addition to KYN, the irradiation of L-tryptophan by visible light [94] or UV light will generate
6-formylindolo[3,2-b]carbazole (FICZ) through photolysis [93]. However, studies have found that FICZ
can be generated via light-independent routes; such as through ROS via indole-3-acetalaldehyde [96].
FICZ is a high-affinity AhR agonist; similar potency to that of TCDD but it can be efficiently metabolised
by the CYP1A1 enzyme [97], and can activate AhR at picomolar concentrations [94]. This contrast to
TCDD allows FICZ to transiently regulate AhR activation and proposes a negative feedback loop for
this pathway [98].
In addition, most indole derivatives are AhR agonists and are derived from the metabolism of
tryptophan, which is an indole itself, by various bacteria from dietary sources [89]. The digestion
of glucobrassicin from cruciferous vegetables; such as broccoli and Brussels sprouts, by stomach
acid leads to the generation of indole-3-carbinol (I3C) and further degradation of this compound
leads to the generation of indolo-[3,2-b]-carbazole (ICZ) and 3,3-diindolylmethane (DIM); both
high-affinity AhR ligands with DIM being less potent than ICZ [91,94]. Lactobacilli have been found to
produce indole-3-aldehyde (IAld) when under carbohydrate-starved conditions through catabolism
of tryptophan via the ‘indole’ pathway [99]. Moreover, indole produced from E.coli metabolism via
tryptophanase is broken down into indoxyl-3-sulfate (I3S) in the liver by the human sulfotransferase
enzyme, SULT1A1 [88,100]. Furthermore, another study found that the intestinal microbiome was able
to generate indole, tryptamine and indole-3-acetate from tryptophan, which all have AhR-mediated
responses [101].
3.2.2. Heme Metabolites
Heme metabolites such as bilirubin and biliverdin have been found to have low-affinity agonistic
AhR properties [97,98]. An early study by Sinal and Bend demonstrated the ability of bilirubin to
induce Cyp1a1 gene expression in mouse hepatoma hepa 1c1c7 cells through an AhR-dependent
pathway [102]. This was further supported in another study that suggested the potential for bilirubin
as an AhR ligand due to the correlation between congenital jaundice Gunn rat and persistent CYP1A1
gene expression in these rats [103]. Homeostatic control of bilirubin serum concentration is important
as this anti-oxidative compound has been implicated as a neurotoxin in newborns and Gilbert’s
syndrome and Crigler–Najjar syndrome. These disorders arise due to a reduced or absent expression
of the UGT1A1 enzyme, which is the major enzyme that detoxifies bilirubin [97]. The participation
of CYP1A1, CYP1A2 and UGT1A in heme catabolism suggests a negative feedback loop on AhR
activation due to the removal of physiologically relevant agonists [93]. Biliverdin and heme, being a
precursor of bilirubin formation, was also shown to indirectly induce CYP1A1 gene expression through
the heme metabolism pathway; while also inducing luciferase activity through AhR transformation
and XRE binding in human and some rodent species, as well as competitively inhibit TCDD binding to
AhR [102,103].
3.2.3. Arachidonic Acid Derivatives
Arachidonic acid (AA) derivatives have been implicated to be endogenous ligands of AhR
due to their metabolism by cytochrome P450 enzymes [104,105], which leads to the induction of
CYP1A1 [106]. Cyclooxygenase-2 (COX-2) has been found to be induced following the TCDD-activation
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of AhR, which leads to the release of prostaglandins [107]; another potential ligand of AhR.
Several prostaglandins were found to be weak agonists of AhR, with prostaglandin G2 being the
most potent and capable of competitively displacing [3H]TCDD bound to AhR [108]. Lipoxin A4 was
also found to be another AhR ligand, activating AhR in Hepa-1 cells, with lipoxin A4 competitively
inhibiting the CYP1A1 enzyme [109]. However, due to their weak agonistic nature and difference in
structure from other AhR ligands, AA may not be biologically relevant [91,93].
3.3. AhR Canonical Pathway
The NLRP3 inflammasome is activated through multiple pathways; similarly, the activation of
AhR can be categorised into the canonical and non-canonical activation pathways. The canonical
pathway of AhR activation (Figure 3) begins with AhR forming an inactive, multi-protein complex in the
cytoplasm with its 90 kDa chaperone protein, heat shock protein 90 (HSP90) and several scaffold protein;
the co-chaperone, p23, the AhR interacting protein (AIP, also known as XAP2 or Ara9) [89,93,110],
the kinome chaperone, Cdc37 and c-SRC protein kinase [111–114]. In this stable state, Hsp90 maintains
the high-affinity ligand binding conformation and functional properties of AhR activation [93,115]
whereas AIP prevents the degradation and ubiquitination of AhR [93,116]. Upon ligand binding,
AhR undergoes a conformational change which exposes its nuclear translocation signal and releases it
from its chaperone protein. However, Tsuji et al. contradicted this when they demonstrated that Hsp90
remains bound to this complex [117], to allow its translocation to the nucleus and heterodimerises with
its nuclear partner, AhR nuclear translocator (ARNT), to form a ligand-AhR-ARNT complex [89,93,110].
Once in the nucleus, the ligand-AhR-ARNT complex binds to its cognate DNA consensus sequence
(5′-TNGCGTG-3′); which is also known as the xenobiotic response element (XRE), located upstream
of the Cytochrome P450 (CYP)1A1 and AhR repressor (AhRR) genes and lead to gene transcription
of several metabolising enzymes. These include phase 1 xenobiotic-metabolising enzymes; such as
Cyp1a2 and Cyp1b1, and phase 2 xenobiotic-metabolising enzymes; such as glutathione-S-transferase
A, NAD(P)H: quinone oxidoreductase 1, uridine 5′–diphosphate-glucuronosyltransferase 1A (UGT1A)
and aldehyde dehydrogenase 3 [89,93,110]. Following its export from the nucleus, AhR undergoes
proteasomal degradation through covalent binding with E3 ubiquitin ligase [88,118].
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3.4. AhR Non-Canonical Pathway
The non-canonical AhR activation pathway is categorised by AhR-mediated gene transcription
that does not contain XRE elements; through ligand-independent mechanisms, direct interactions
with the protein and regulating phosphorylation events in the cytoplasm and nucleus [119]. There is
evidence that shows cross-talk between AhR and the NF-κB subunit, RelB through the binding with
the XRE-like sequence, CC-chemokine ligand 1 (CCL1), located at the IL-8 gene regulatory region [120].
AhR has also been shown to directly interact with the oestrogen receptor by acting as an E3 ubiquitin
ligase and facilitating its degradation [121–123]. Several studies have also shown that AhR can directly
bind with the retinoblastoma receptor and the E2F promoter to form a complex that leads suppression
of S phase-specific genes and the arrest of the cell cycle at the G1 phase [124–126]. In addition,
Kruppel-like Factor 6 (KLF6); a tumour suppressor through regulation of the p21Cip1 cyclin-dependent
kinase inhibitor [127,128], has been identified as a novel DNA-binding partner of AhR to express
inducible-TCDD when bound at the non-consensus XRE [129,130].
3.5. Regulation of AhR Activation
In order to maintain a healthy cell physiology, the activation of AhR has to be regulated. There are
various ways that maintain this homeostasis. Firstly, following its export out of the nucleus by a
nuclear export signal (NES), the ligand-activated AhR is broken down by the 26S ubiquitin-proteosome
system [119,131]. Secondly, the phase I and II xenobiotic metabolising enzymes are responsible
for an auto-regulatory feedback loop with AhR activation [94]. The upstream activation signal
of these enzymes by AhR leads to the degradation of AhR ligands and prevent prolonged AhR
activation [94,110]. Thirdly, the activation of AhR also leads to the transcription of the AhRR, which is
an AhR inhibitor. AhRR inhibits AhR activity by direct competition with AhR for binding with ARNT;
in which AhRR has a higher affinity for ARNT than AhR, thus interfering with the AhR-ARNT complex
to prevent its binding with DNA and leads to AhR proteosomal degradation [94,110,119]. It should
be noted that AhRR expression does not always correspond with CYP1A1 induction; even though
AhR-mediated transcription leads to the expression of both AhRR and CYP1A1 [132]. This indicates
AhRR may also be involved with other signalling pathways and have other cellular functions, since the
Ahrr genes contain binding sites that are recognised by the NF-κB and zinc-finger transcription factors
of the Sp1 family [132]. Lastly, the mono-ADP-ribosyltransferase, TCDD-inducible Poly ADP-Ribose
Polymerase (TiPARP), has been shown in several studies to negatively regulate AhR transactivation;
comparably with AhRR but utilising different mechanisms, through a negative feedback loop in the
AhR signalling pathway and modulating its expression [133–136].
3.6. AhR in Inflammation-Related Diseases
A prominent case of AhR influencing immunity is the failed assassination attempt by TCDD
poisoning of the 2004 Ukraine president candidate, Victor Yushchenko [137]. TCDD diffuses freely
across the plasma membrane and exerts its toxic properties when bound to AhR; which lead to Viktor
developing symptoms of acute pancreatitis and chloracne at a concentration of 50,000-fold to the normal
TCDD concentration of the general population [137,138]. This incident has led to extensive research on
AhR to elucidate its roles in immune system disorders; such as in microbial infections, major depressive
disorder, multiple sclerosis, congenital nystagmus, inflammatory diseases, autoimmune diseases and a
wide range of cancers [139,140]. The link between AhR and the gut is extensively studied due to AhR
being highly expressed in the gut [140]. There is increasing evidence of AhR dampening the immune
response in inflammatory diseases that include types of IBD; such as CD and UC [89] through its
involvement with NLRP3. A recent study had determined a link between NLRP3 and AhR in preschool
children. This study found that PAH exposure, an environmental ligand of AhR, lead to an increased
expression of several pro-inflammatory cytokines regulated by the NLRP3 inflammasome, which lead
to cytokine storms developing in these children [140]. Another study by Postal et al. found a role
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for AhR in maintaining intestinal barrier integrity; concluding that AhR elicited a protective effect by
cross-talking with several signalling pathways that promoted the maintenance of tight junctions [141].
4. Therapeutic Application of AhR in IBD and CAC
4.1. AhR Acts as a Natural NLRP3 Inhibitor
While PTMs play an important role in the regulation of the NLRP3 inflammasome activation,
it can also be regulated through modifications at the transcription level with NF-κB. As previously
mentioned, NF-κB plays a central role in the priming step and leads to the formation of pro-IL-1β,
pro-IL-18 and the NLRP3 protein; which is needed for the activation of the NLRP3 inflammasome,
following stimulation of the TLRs by Signal 1 [141,142]. Afonina et al. have identified several negative
regulators of the NF-κB pathway that inhibit NLRP3 inflammasome activation, which may be the
potential therapeutic target for inflammatory and autoimmune diseases [143].
Besides NF-κB, AhR has been shown to play a part in the innate immune response; such as in
Listeria monocytogenes (LM) infections, where Kimura et al. revealed that AhR knockout macrophages
had increased expression of the pro-inflammatory cytokines, IL-6 and TNF-α, and promoted caspase-3
activation; which lead to decreased macrophage survival and increased susceptibility to listeriosis [144].
The study further described that AhR also induces the expression of p40phox and the production
of ROS, which further enhanced bacterial clearance during LM infection [144]. AhR and the NLRP3
inflammasome has been implicated in a study by Jia et al., which determined that their link was
associated with the pathogenesis of acute myeloid leukaemia and an imbalance in the TH population;
through measuring AhR and NLRP3 molecules in the bone marrow and peripheral mononuclear
cells of newly diagnosed and remission patients [145]. Importantly, the myeloid-specific microRNA,
miR-223 was identified as a negative regulator of the NLRP3 inflammasome through transcriptional
control at NLRP3 3′-UTR [146,147]. Coincidentally, Ogando et al. determined that miR-223 acts
as a regulator of the AhR/ARNT pathway and its expression leads to the down-regulation of the
AhR/ARNT and increased pro-inflammatory cytokine production in rheumatoid arthritis patients [148].
Interestingly, miR-223 is a common regulator of both the AhR/ARNT and NLRP3 activation pathways.
The link between AhR and NF-κB was identified by Tian et al. who described that AhR and NF-κB
RelA directly interact with each other by physical association and functional modulation following
dissociation from their respective regulatory mechanisms after stimulation by their respective activation
signals [149]. The study also proposes two mechanism models that may explain their mutual repression
following their interaction; which are, the formation of an inactive complex or regulation by the
transcription mediator p300/CREB-binding protein (CBP) that leads to competitive binding between
ligand-AhR/ARNT complexes and RelA for p300/CBP [149]. This notion is supported by another
study that determined NF-κB and the glucocorticoid receptor mutually repressed each other through
the co-activators, CBP and steroid receptor coactivator-1 (SRC-1) [150]. In addition to NF-κB RelA,
NF-κB RelB was also found to crosstalk with AhR [151,152]. Another link between AhR and the NF-κB
pathway was demonstrated by Wang et al., in which they exemplified that quaking plays a role in
inhibiting innate immune responses via regulation of the AhR/STAT1–NF-κB pathway [153].
The interactions between AhR and NF-κB lead to the hypothesis that AhR can also regulate
NLRP3 inflammasome activity via the NF-κB pathway (Figure 4). A critical study by Huai et al.
determined that AhR negatively regulates NLRP3 inflammasome activation at the transcriptional level
via the NF-κB pathway by using TCDD-treated, LPS-induced mouse peritoneal macrophages to show
reduced Nlrp3 expression at the protein and mRNA level [154]. They also identified that the inhibitory
action was due to AhR binding to XRE sequences at the two NF-κB binding sites located in the NLRP3
promoter region [154]. Their proposed mechanism models were that NLRP3 acted as the rate-limiting
element in its activation and that either AhR competed with NF-κB for binding sites or that AhR
‘tethered’ NF-κB to prevent the transcriptional process [154]. AhR has also been shown to negatively
regulate LPS-induced inflammatory responses through its interactions with the NF-κB pathway via
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Stat1 to inhibit IL-6 activities [155] and via plasminogen activator inhibitor-2 (Pai-2) to inhibit IL-1β
expression [156]. In addition to that, Zhu et al. also illustrated that the NF-κB pathway mediated
LPS-induced AhR expression in macrophages [157]. However, it should be noted that a controversial
study found that indoxyl sulfate-induced the expression of macrophage IL-1β via AhR-NF-κB/MAPK
cascade, while bypassing NLRP3 activation [158]. This result may be specific to sustained chronic
inflammation in the kidneys and may utilise different mechanisms than that of chronic colitis.
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4.2. Role of Mouse Models in the Investigation of AhR in Maintaining Intestinal Homeostasis
AhR and its effects on the NLRP3 inflammasome and colitis have been predominantly studied
using wild-type (AhR+/+), AhR knockout (AhR−/−) and heterozygous (AhR−/+) ouse odels that have
been chemically induced with intestinal inflammation; by using 2,4,6-trinitrobenzene sulphonic acid
(TNBS) or dextran sulphate sodium (DSS), and CAC; by using azoxymethane (AOM or AOM/DSS) [70].
Several studies have determined that AhR exhibits protective effects during intestinal inflammation;
with TCDD-treated and FICZ-treated mice ameliorating colitis severity, which were determined from
corrected weight loss, reduced colitis symptoms and recover periods [159–163]. These reversed colitis
effects were due to a change in their cytokine environment, with AhR-activated mice having a reduction
in the expression of pro-inflammatory mediators; such as IL-6, IL-12, IL-17, IFN-c, MCP-1, exotaxin-1
and TNF-α, but an increase in IL-22 and TGF-β [159,162,163]. The results from Monteleone et al.
supports this notion with FICZ-treated TNBS-induced mice showing reversed colitis symptoms
while also showing that colitis symptoms were enhanced when the mice were treated with AhR
antagonists [164]. They further determined a link between FICZ and IL-22; with FICZ increasing the
expression of IL-22, and anti-IL-22 leading to a reduction in the anti-inflammatory effects of FICZ [164].
Takamura et al. proposed that the inhibition of colitis by AhR may be due to the production of PGE2; and
that the inhibition of PGE2 reduced the inhibitory effects of AhR on colitis [165]. Furumatsu et al. found
that AhR knockout mice displayed more severe DSS-induced colitis when compared to the C57BL/6J
wild-type mice [166]. In accordance to that, Arsenescu et al. proclai ed that wild-type mice developed
severe colitis and AhR knockout mice died early in inflammation; but heterozygous mice exhibited
little change in intestinal histology and had good clinical outcomes [167]. These heterozygous mice had
reduced expression of TNF-α as compared to the other two models [167]. The disparity of results seen
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in these mouse models suggests more investigations to be done in order to achieve a greater insight
into the mechanisms involved in the protective roles of AhR in maintaining intestinal homeostasis.
4.3. Therapeutic Potential of AhR as A Natural NLRP3 Inflammasome Inhibitor
The understanding of the signalling pathways of AhR and the NLRP3 inflammasome and how
they intertwine with each other is important in assessing the therapeutic potential of AhR in the
treatment of IBD and CAC (Table 1). The abundance of natural AhR ligands found in the environment
provides a positive outlook for future therapeutic agents that utilise AhR as an immunomodulator
through its inhibitory effects on NLRP3 inflammasome activation. We have identified some NLRP3
inhibitors that utilise the AhR pathway have been described in an experimental context and have been
demonstrated to be effective.
4.3.1. Therapeutic Potential of AhR as A Natural NLRP3 Inflammasome Inhibitor in
Bowel Inflammation
Norisoboldine (NOR) is the primary isoquinoline alkaloid constituent of Radix Linderae; the dry
root of Lindera aggregata (Sims) Kosterm (L. strychnifolia Vill), which is commonly used in Chinese
medicine in treating a variety of ailments, which include constipation, polyuria, dyspepsia, acute and
chronic colitis, chest and abdominal pain and rheumatism palsy [168,169]. NOR has been shown to
be a natural AhR ligand by Qi et al. through its up-regulation of CYP1A1 expression, promotion of
AhR nuclear translocation after dissociation of the AhR/Hsp90 complex and transcriptional activity of
AhR/ARNT via DNA binding to the XRE region in THP-1 cells [169]. Studies also reveal that NOR
promotes Treg cell differentiation from naïve T-cells in-vitro and increased its immunosuppressive effects
on Teff cells through inducing apoptotic events and inhibiting Th1 and Th17 differentiation [170,171].
In the context of IBD, NOR has also been demonstrated to reduce NLRP3, ASC and caspase-1 expression
in TNBS-induced mice, which could imply that NOR has inhibitory effects on NLRP3 inflammasome
activation through an AhR pathway [169]. The study further found a link between NOR and Nrf2,
a nuclear transcriptional factor of Cap’n’ Collar family that can inhibit NLRP3 priming [172], as the
mechanism for NOR-induced inhibition of NLRP3 inflammasome activation; where NOR up-regulated
the expression of Nrf2 but down-regulated the production of ROS signals in THP-1 cells [169].
Concurrently, Qi et al. also demonstrated that NOR was able to produce anti-UC effects through the
suppression of glycolysis and promotion of Treg cell differentiation in hypoxic microenvironments via
regulation of the NAD+/SIRT1/SUV39H1/H3K9me3 signalling pathway [170].
Cardamonin (20,40-dihydroxy-60-methoxychalcone) is a chalcone that is the main flavonoid
isolated from the dry, mature seeds of the medicinal herb, Alpinia katsumadai Hayata [173–175]. It has
been used for thousands of years as a traditional Chinese medicine due to its anti-inflammatory
and anti-tumour properties [173–175]. The anti-inflammatory activity of cardamonin was studied by
Wang et al., in which they demonstrated that cardamonin inhibited NLRP3 inflammasome expression
and activation in mice colon with TNBS- and DSS-induced colitis and LPS- and ATP-stimulated
macrophages [175]. They further displayed that AhR and Nrf2 were also influenced by cardamonin as
evidenced by the up-regulation of CYP1A1 mRNA and protein levels, and the up-regulation of Nrf2
protein levels in THP-1 cells, respectively [175]. The AhR/Nrf2 signals produced by cardamonin would
then activate NQO1, which has inhibitory effects in NLRP3 inflammasome priming, which lead to a
reduction in pro-inflammatory cytokines and produce anti-colitis effects [172,175]. Further studies
by Wang et al. revealed that cardamonin acts a broad-spectrum and specific inhibitor of the NLRP3
inflammasome through their mouse models which show that cardamonin increased the survival rate
of mice with LPS-induced septic shock and down-regulated expression of TNF-α and IL-1β [174].
4.3.2. Therapeutic Potential of AhR as a Natural NLRP3 Inflammasome Inhibitor in CAC
An early study discovered the link between AhR and colon neoplasia when they characterised
the association of AhR with the human colon adenocarcinoma cell line LS180 [176]. This link was
Molecules 2020, 25, 2427 15 of 25
also observed in a study that utilised mouse models with sporadic colon cancer that were fed a
Western-style diet; in which oxidative stress response and immune dysregulation via Nrf2 and
AhR pathways were induced [177]. Another study using AOM/DSS-induced mouse models found
that the absence of AhR increased their susceptibility in colorectal tumorigenesis. The same study
also found that the AhR ligand, I3C protected against the development of colorectal tumours and
is AhR-dependent [178]. The association between the NLRP3 inflammasome and AhR in CAC
was shown in a study by Ikuta et al., in which cecal tumours developed in AhR-null mice in an
ASC-dependent manner. This same study also determined that AhR plays dual tumour suppressor
roles; as a regulator of intestine anti-inflammation and β-catenin degradation [179]. Cardamonin
was also shown to have protective effects against tumorigenesis via AhR. The anti-tumour activity
of cardamonin was explored by Wang et al., which indicated that cardamonin exerts anti-gastric
cancer properties by down-regulating signal transducer and activator of transcription 3 (STAT3) via
the LncRNA-PVT1-STAT3 signalling pathway in human gastric cells, AGS [173].
Table 1. Roles of the NLRP3 inflammasome and AhR in inflammation and cancer.
Pathways Mechanism Ref.
AhR/STAT1–NF-κB axis Quaking inhibits NF-κB transcriptional activity and preventsNLRP3 inflammation via AhR-dependent manner [153]
NAD+/SIRT1/SUV39H1/H3K9me3 axis Ameliorates colitis through promotion of Treg differentiation [170]
LncRNA-PVT1-STAT3 axis Inhibits STAT3 via LncRNA-PVT1 from promoting signals forcancer inflammation [173]
AhR/Nrf2/NQO1 axis AhR up-regulates Nrf2 and NQO1 levels in the colon and preventsNLRP3 inflammasome activation [175]
Fibronectin/integrin β1/FAK axis Promotes cancer metastasis through ANRT down-regulation [180]
While NOR and cardamonin have been described to naturally inhibit NLRP3 activation and
reducing the inflammatory effects via AhR, more studies should be conducted to expand the variety of
these natural inhibitors.
5. Conclusions
It is clear that there is substantial evidence that supports the role that AhR plays as a natural
inhibitor of the NLRP3 inflammasome at the transcriptional level. AhR acts as the primary link between
nature and the immune system due to the abundance of its ligands found in the environment and
our daily consumptions. Indeed, its link to the NLRP3 inflammasome also validates the role AhR
can play in the treatment of colitis in IBD and CAC. The exact mechanisms behind the crosstalk of
these signalling pathways are under vigorous investigation, however, the current models proposed for
this mechanism are still matters of conjecture. Promisingly there are successful therapeutic agents
determined to be AhR agonists that treat TNBS- and DSS-induced colitis via the NLRP3 inflammasome
but they are still far from many. Thus, follow-up studies are essential to look further into deciphering
the precise mechanisms of NLRP3 inflammasome inhibition by AhR. This will open a pathway for the
use of AhR-dependent therapeutic agents; as an alternative treatment method of IBD and CAC, that
may prove to be more potent and possibly a safer option as compared to current treatment methods.
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Abbreviations
AA Arachidonic acid
AhR Aryl hydrocarbon receptor
AhRR Aryl hydrocarbon receptor repressor
ARNT Aryl hydrocarbon receptor nuclear translocator
bHLH Basic helix–loop–helix




DAMP Danger-associated molecular pattern
DSS Dextran sulfate sodium
FICZ 6-formylindolo(3,2b)carbazole
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GSDMD-D Gasdermin D
HAH Halogenated aromatic hydrocarbon
HSP90 Heat shock protein 90




MAVS Mitochondrial antiviral-signalling protein
MyD88 Myeloid differentiation primary response 88
NEK7 NIMA-related kinase 7
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NLR Nod-like receptor
NLRP3 Nod-like receptor family pyrin domain containing 3
NOR Norisoboldine
PAH Polycyclic aromatic hydrocarbons
PAMP Pathogen-associated molecular pattern




TNBS 2,4,6-trinitrobenzene sulfonic acid
UC Ulcerative colitis
XRE Xenobiotic responsive element
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